Tempus AI (NASDAQ:TEM) Trading 9.3% Higher – Time to Buy?

06 Jun 2026, 07:46 by Jessica Moore · The Cerbat Gem

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report)’s stock price traded up 9.3% during mid-day trading on Thursday . The company traded as high as $51.40 and last traded at $51.9130. 2,426,541 shares were traded during trading, a decline of 57% from the average session volume of 5,704,903 shares. The stock had previously closed at $47.51.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday. They set a “peer perform” rating on the stock. BTIG Research reiterated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Robert W. Baird assumed coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target on the stock. Finally, HC Wainwright cut their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $68.64.

Check Out Our Latest Report on Tempus AI

Tempus AI Price Performance

The stock has a fifty day moving average of $48.89 and a 200-day moving average of $57.48. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $8.34 billion, a price-to-earnings ratio of -26.99 and a beta of 3.62.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share. On average, equities research analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 10,853 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total value of $478,291.71. Following the completion of the transaction, the chief financial officer directly owned 126,395 shares of the company’s stock, valued at $5,570,227.65. This represents a 7.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the transaction, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at $3,262,986.87. This trade represents a 5.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 558,557 shares of company stock valued at $26,611,939 over the last three months. 24.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC boosted its holdings in Tempus AI by 1.3% in the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock valued at $1,944,000 after purchasing an additional 536 shares in the last quarter. Avidity Partners Management LP acquired a new stake in shares of Tempus AI in the first quarter valued at approximately $1,130,000. Silverback Asset Management LLC boosted its holdings in shares of Tempus AI by 44.5% in the first quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock valued at $1,614,000 after acquiring an additional 11,000 shares during the period. Vestor Capital LLC boosted its holdings in shares of Tempus AI by 338.2% in the first quarter. Vestor Capital LLC now owns 1,538 shares of the company’s stock valued at $70,000 after acquiring an additional 1,187 shares during the period. Finally, Arkadios Wealth Advisors boosted its holdings in shares of Tempus AI by 9.6% in the first quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after acquiring an additional 435 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.